Pesquisar
InflaRx NV
IFRXAdicionar à lista de desejos
2.090USD
-0.080-3.69%
Fechamento 09-09 16:00（ET）
308.00MValor de mercado
PerdaP/L TTM
Mais detalhes de InflaRx NV Empresa
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Perfil
Código da empresaIFRX
Nome da EmpresaInflaRx NV
Data de listagemNov 08, 2017
CEORiedemann (Niels C)
Número de funcionários74
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 08
EndereçoWinzerlaer Str. 2
CidadeJENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal07745
Telefone493641508180
Sitehttps://www.inflarx.de/
Código da empresaIFRX
Data de listagemNov 08, 2017
CEORiedemann (Niels C)
Executivos da empresa InflaRx NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de InflaRx NV?
Os cinco principais acionistas de InflaRx NV são: Mr. Nicolas Fulpius
Quantas instituições possuem ações da InflaRx NV (IFRX)?
Em 2026Q1, 82 instituições possuíam ações da InflaRx NV, com valor de mercado aproximado de 19.59M, representando 13.30% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -4596250.00.